The Food and Drug Administration is warning Lexington, Mass.-based Kaleido Biosciences that it shouldn’t have tested one of its microbiome therapeutics in humans without filing the paperwork the agency requires to begin clinical trials.
The FDA’s warning letter, published in late August and reported first by Endpoints, focuses only on a microbiome therapeutic that Kaleido was testing as a Covid-19 treatment.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
